A 28-year-old female with a history of chronic kidney disease (eGFR 25 mL/min) sustains a tibial shaft fracture. Her serum calcium is 7.2 mg/dL and phosphate is 5.8 mg/dL. She is at high risk for impaired fracture healing due to secondary hyperparathyroidism and mineral metabolism derangement. Which agent should be administered to optimize fracture healing in this setting?
A. Cholecalciferol (vitamin D₃)
B. Alfacalcidol
C. Calcitriol (active vitamin D)
D. Ergocalciferol (vitamin D₂)
Explanation
Vitamin D Metabolism and Fracture Healing in Renal Impairment
The Problem in Chronic Kidney Disease
Key Point
In CKD, the kidneys cannot adequately convert 25-hydroxyvitamin D to the active form (1,25-dihydroxyvitamin D₃ or calcitriol) due to reduced 1-alpha-hydroxylase activity. This leads to:
Hypocalcaemia (as seen: Ca 7.2 mg/dL)
Hyperphosphataemia (as seen: PO₄ 5.8 mg/dL)
Secondary hyperparathyroidism
Impaired osteoblast function and fracture healing
Vitamin D Forms and Activation Pathway
Table
Agent
Form
Activation Required
Use in CKD
Calcitriol
1,25-diOH-D₃
None — already fully active
Effective, but narrow therapeutic window; risk of hypercalcaemia
Cholecalciferol (D₃)
Parent compound
Liver + kidney hydroxylation
Ineffective in significant CKD
Ergocalciferol (D₂)
Parent compound
Liver + kidney hydroxylation
Ineffective in significant CKD
Alfacalcidol
1-alpha-OH-D₃
Liver hydroxylation only
Preferred in CKD — bypasses renal step
Why Alfacalcidol is the Preferred Agent in CKD
High-YieldNEET PG
Alfacalcidol (1α-hydroxycholecalciferol) requires only hepatic 25-hydroxylation to become fully active calcitriol — it bypasses the deficient renal 1-alpha-hydroxylase step entirely. This makes it the preferred vitamin D analogue in CKD patients for:
1.
Correcting hypocalcaemia and suppressing secondary hyperparathyroidism
2.
Stimulating osteoblast differentiation and alkaline phosphatase production
3.
Promoting fracture callus mineralization and bone healing
4.
Providing a more physiological and titratable response compared to calcitriol
Clinical Pearl
While calcitriol is also active without renal conversion, alfacalcidol is the drug of choice in CKD-related mineral bone disease and fracture healing in standard nephrology/orthopedics practice (as per KDIGO guidelines and KD Tripathi Essentials of Medical Pharmacology). Alfacalcidol offers a slightly wider therapeutic window because its conversion to calcitriol via the liver is regulated, reducing the risk of abrupt hypercalcaemia seen with direct calcitriol use.
Warning
Ergocalciferol or cholecalciferol require intact renal 1-alpha-hydroxylase and are ineffective for fracture healing support in CKD. Calcitriol, while active, is second-line due to its narrow therapeutic index and risk of hypercalcaemia in CKD patients.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed., Chapter on Vitamins and Minerals; KDIGO CKD-MBD Guidelines 2017.
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
